Piper Sandler assumed coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report report published on Thursday morning, BenzingaRatingsTable reports. The firm issued an overweight rating on the stock.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Mirum Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 8th. Raymond James reiterated an outperform rating and issued a $28.00 price objective (down from $30.00) on shares of Mirum Pharmaceuticals in a report on Friday, May 8th. ValuEngine cut Mirum Pharmaceuticals from a buy rating to a hold rating in a report on Monday, July 20th. Finally, Robert W. Baird started coverage on Mirum Pharmaceuticals in a report on Wednesday, June 24th. They issued an outperform rating and a $30.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $26.14.

Shares of NASDAQ:MIRM traded up $0.70 during trading on Thursday, reaching $22.08. 69,097 shares of the company’s stock traded hands, compared to its average volume of 42,048. Mirum Pharmaceuticals has a fifty-two week low of $6.51 and a fifty-two week high of $28.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.99 and a quick ratio of 11.99. The company has a 50-day simple moving average of $19.72 and a 200-day simple moving average of $16.91.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Thursday, May 7th. The company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.82) by ($0.04). As a group, equities analysts expect that Mirum Pharmaceuticals will post -3.61 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of MIRM. Marshall Wace North America L.P. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $25,000. Victory Capital Management Inc. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $32,000. American International Group Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 83.1% during the 1st quarter. American International Group Inc. now owns 3,083 shares of the company’s stock worth $43,000 after purchasing an additional 1,399 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Mirum Pharmaceuticals by 1,465.1% during the 1st quarter. Wells Fargo & Company MN now owns 3,678 shares of the company’s stock worth $51,000 after purchasing an additional 3,443 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Mirum Pharmaceuticals by 93.2% during the 1st quarter. JPMorgan Chase & Co. now owns 8,264 shares of the company’s stock worth $116,000 after purchasing an additional 3,987 shares during the last quarter. Institutional investors and hedge funds own 73.27% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Featured Article: How Investors Can Profit from Options Trading

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.